Masato Katagiri

2.7k total citations
94 papers, 2.1k citations indexed

About

Masato Katagiri is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Masato Katagiri has authored 94 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 46 papers in Pulmonary and Respiratory Medicine, 37 papers in Oncology and 20 papers in Molecular Biology. Recurrent topics in Masato Katagiri's work include Lung Cancer Treatments and Mutations (30 papers), Lung Cancer Research Studies (17 papers) and Pharmacogenetics and Drug Metabolism (10 papers). Masato Katagiri is often cited by papers focused on Lung Cancer Treatments and Mutations (30 papers), Lung Cancer Research Studies (17 papers) and Pharmacogenetics and Drug Metabolism (10 papers). Masato Katagiri collaborates with scholars based in Japan, Canada and United States. Masato Katagiri's co-authors include I. C. Gunsalus, Katsuko Suhara, B. N. GANGULI, Shigeki Takemori, Hiroshi Sato, Tadashi Gomi, Eiji Itagaki, Paul A. Easton, Masanori Yokoba and Satoshi Igawa and has published in prestigious journals such as Science, Journal of the American Chemical Society and Journal of Biological Chemistry.

In The Last Decade

Masato Katagiri

93 papers receiving 2.0k citations

Peers

Masato Katagiri
Mark J. Rose United States
Dennis J. O’Kane United States
Gunnar Boysen United States
David J. Elliot Australia
Charles A. Tyson United States
Scott Grossman United States
Grover P. Miller United States
Gerald D. Nordblom United States
Masato Katagiri
Citations per year, relative to Masato Katagiri Masato Katagiri (= 1×) peers Jun Watanabe

Countries citing papers authored by Masato Katagiri

Since Specialization
Citations

This map shows the geographic impact of Masato Katagiri's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Masato Katagiri with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Masato Katagiri more than expected).

Fields of papers citing papers by Masato Katagiri

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Masato Katagiri. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Masato Katagiri. The network helps show where Masato Katagiri may publish in the future.

Co-authorship network of co-authors of Masato Katagiri

This figure shows the co-authorship network connecting the top 25 collaborators of Masato Katagiri. A scholar is included among the top collaborators of Masato Katagiri based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Masato Katagiri. Masato Katagiri is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Kawakami, Fumitaka, Motoshi Ouchi, Masanori Yokoba, et al.. (2022). In vitro study on effect of bardoxolone methyl on cisplatin-induced cellular senescence in human proximal tubular cells. Molecular and Cellular Biochemistry. 477(3). 689–699. 14 indexed citations
2.
Igawa, Satoshi, Masashi Kasajima, Hideaki Manabe, et al.. (2020). <p>Impact of Amrubicin Monotherapy as Second-Line Chemotherapy on Outcomes in Elderly Patients with Relapsed Extensive-Disease Small-Cell Lung Cancer</p>. Cancer Management and Research. Volume 12. 4911–4921. 2 indexed citations
3.
Igawa, Satoshi, Tomoya Fukui, Jiichiro Sasaki, et al.. (2020). Impact of neutrophil-to-lymphocyte ratio in patients with EGFR-mutant NSCLC treated with tyrosine kinase inhibitors. Investigational New Drugs. 38(3). 885–893. 14 indexed citations
4.
Igawa, Satoshi, Masashi Kasajima, Yasuhiro Hiyoshi, et al.. (2019). <p>Impact of <em>EGFR </em>genotype on the efficacy of osimertinib in <em>EGFR </em>tyrosine kinase inhibitor-resistant patients with non-small cell lung cancer: a prospective observational study</p>. Cancer Management and Research. Volume 11. 4883–4892. 17 indexed citations
6.
Shirasawa, Masayuki, Tomoya Fukui, Yasuhiro Hiyoshi, et al.. (2018). Prognostic significance of the 8th edition of the TNM classification for patients with extensive disease small cell lung cancer. Cancer Management and Research. Volume 10. 6039–6047. 18 indexed citations
7.
Igawa, Satoshi, Akira Takakura, Hideyuki Sone, et al.. (2018). Real-world evaluation of carboplatin plus a weekly dose of nab-paclitaxel for patients with advanced non-small-cell lung cancer with interstitial lung disease. Cancer Management and Research. Volume 10. 7013–7019. 9 indexed citations
8.
Igawa, Satoshi, Masayuki Shirasawa, Tomoya Fukui, et al.. (2018). Efficacy of Platinum-Based Chemotherapy for Relapsed Small-Cell Lung Cancer after Amrubicin Monotherapy in Elderly Patients and Patients with Poor Performance Status. Oncology. 94(4). 207–214. 4 indexed citations
9.
Kasajima, Masashi, Satoshi Igawa, Sakiko Otani, et al.. (2017). Correlation between the efficacy of amrubicin and the previous chemotherapy regimen for relapsed small cell lung cancer. Oncology Letters. 13(3). 1719–1724. 4 indexed citations
10.
Fukui, Tomoya, Yoshiro Nakahara, Sakiko Otani, et al.. (2017). A prospective observational study of immune checkpoint inhibitor nivolumab treatment in patients with non-small cell lung cancer. Annals of Oncology. 28. x135–x135. 1 indexed citations
11.
Igawa, Satoshi, Sakiko Otani, Yoshiro Nakahara, et al.. (2017). Phase I study of Nedaplatin, a platinum based antineoplastic drug, combined with nab-paclitaxel in patients with advanced squamous non–small cell lung cancer. Investigational New Drugs. 36(1). 45–52. 3 indexed citations
12.
Igawa, Satoshi, Yuichi Sato, Shinichiro Ryuge, et al.. (2017). Impact of PD-L1 Expression in Patients with Surgically Resected Non-Small-Cell Lung Cancer. Oncology. 92(5). 283–290. 34 indexed citations
13.
Fujimura, Naoyuki, et al.. (2015). Ventilation and diaphragm activity during sustained hypoxia in awake canines. Respiratory Physiology & Neurobiology. 217. 32–39. 1 indexed citations
14.
Fukui, Tomoya, Sakiko Otani, Ryuji Hataishi, et al.. (2009). Successful rechallenge with erlotinib in a patient with EGFR-mutant lung adenocarcinoma who developed gefitinib-related interstitial lung disease. Cancer Chemotherapy and Pharmacology. 65(4). 803–806. 28 indexed citations
15.
Katagiri, Masato, et al.. (2008). Drug interactions between warfarin and a combination of paclitaxel and carboplatin in a non-small cell lung cancer patient. 38(1). 59–62. 2 indexed citations
16.
Yokoba, Masanori, Michiko Yamamoto, Shinichiro Ryuge, et al.. (2006). Phase I and pharmacologic study of irinotecan and amrubicin in advanced non-small cell lung cancer. Cancer Chemotherapy and Pharmacology. 59(4). 419–427. 11 indexed citations
17.
Mitsufuji, Hisashi, Shinichiro Ryuge, Emi H. Kato, et al.. (2005). Drug Interaction Between Gefitinib and Warfarin. Japanese Journal of Clinical Oncology. 35(8). 478–482. 18 indexed citations
18.
Katagiri, Masato, Tadashi Abe, Masanori Yokoba, et al.. (2003). Neck and abdominal muscle activity during a sniff. Respiratory Medicine. 97(9). 1027–1035. 25 indexed citations
19.
Ueda, S, Masato Katagiri, Y. Matsumoto, et al.. (2001). Nitric Oxide-dependent Inhibition of Platelet Aggregation in Elderly Patients with Hypercholesterolemia.. Nippon Ronen Igakkai Zasshi Japanese Journal of Geriatrics. 38(2). 177–184. 1 indexed citations
20.
Katagiri, Masato, et al.. (1998). Diaphragm Function during Sighs in Awake Dogs after Laparotomy. American Journal of Respiratory and Critical Care Medicine. 157(4). 1085–1092. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026